"This is a new tool for bad actors to do bad things to the American public."

One $95 billion asset manager is bracing for bond yields to gyrate and for high borrowing costs to weigh on corporate earnings.

An EY study of institutional investors found signals that "the paradigm of maximizing profits at the expense of worker satisfaction is being significantly challenged."

Though J&J is one of the country's largest drugmakers, the lawsuit argues, it failed to use its buying power when purchasing medications to negotiate the best prices for medicines for workers on its health plan.